Generex Biotechnology Corp - ESG Rating & Company Profile powered by AI
This ESG rating includes 17 UN SDGs including: 'Quality Education', 'Responsible Production & Consumption' and 'Partnerships for the Goals'. The Sustainability assessment for Generex Biotechnology Corp represents its transparency towards the United Nations SDGs. Comprehensive ESG assessment of Generex Biotechnology Corp can be accessed by registering for free.
Generex Biotechnology Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Generex Biotechnology Corp | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Generex Biotechnology Corp have an accelerator or VC vehicle to help deliver innovation?
Does Generex Biotechnology Corp disclose current and historical energy intensity?
Does Generex Biotechnology Corp report the average age of the workforce?
Does Generex Biotechnology Corp reference operational or capital allocation in relation to climate change?
Does Generex Biotechnology Corp disclose its ethnicity pay gap?
Does Generex Biotechnology Corp disclose cybersecurity risks?
Does Generex Biotechnology Corp offer flexible work?
Does Generex Biotechnology Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Generex Biotechnology Corp disclose the number of employees in R&D functions?
Does Generex Biotechnology Corp conduct supply chain audits?
Does Generex Biotechnology Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Generex Biotechnology Corp conduct 360 degree staff reviews?
Does Generex Biotechnology Corp disclose the individual responsible for D&I?
Does Generex Biotechnology Corp disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Generex Biotechnology Corp disclose current and / or historical scope 2 emissions?
Does Generex Biotechnology Corp disclose water use targets?
Does Generex Biotechnology Corp have careers partnerships with academic institutions?
Did Generex Biotechnology Corp have a product recall in the last two years?
Does Generex Biotechnology Corp disclose incidents of discrimination?
Does Generex Biotechnology Corp allow for Work Councils/Collective Agreements to be formed?
Has Generex Biotechnology Corp issued a profit warning in the past 24 months?
Does Generex Biotechnology Corp disclose parental leave metrics?
Does Generex Biotechnology Corp disclose climate scenario or pathway analysis?
Does Generex Biotechnology Corp disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Generex Biotechnology Corp disclose the pay ratio of women to men?
Does Generex Biotechnology Corp support suppliers with sustainability related research and development?
Does Generex Biotechnology Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Generex Biotechnology Corp reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Generex Biotechnology Corp involved in embryonic stem cell research?
Does Generex Biotechnology Corp disclose GHG and Air Emissions intensity?
Does Generex Biotechnology Corp disclose its waste policy?
Does Generex Biotechnology Corp report according to TCFD requirements?
Does Generex Biotechnology Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Generex Biotechnology Corp disclose energy use targets?
Does Generex Biotechnology Corp disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Generex Biotechnology Corp have a policy relating to cyber security?
Have a different question?
Potential Risks for Generex Biotechnology Corp
These potential risks are based on the size, segment and geographies of the company.
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.